

**RECEIVED**  
CENTRAL FAX CENTER

NO. 800 0004

JUL 28 2005

PTO-SB-03A (03-00)

Approved for use through 10-31-2002 OMB 0551-0031

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary) Sheet 1 of 1	<b>Application Number</b>	10/719,102
	<b>Filing Date</b>	November 21, 2003
	<b>First Named Inventor</b>	Elfath Elzein
	<b>Group Art Unit</b>	1614
	<b>Examiner Name</b>	Unassigned
	<b>Attorney Docket Number</b>	01-0163-CIP2

## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code <sup>2</sup> (if known)			

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	†
		Office <sup>2</sup>	Number <sup>2</sup>	Kind Code <sup>2</sup>				
W		[EP]	0956855	A	K.U. Research & Development	11/18/99		


Examiner Signature	<i>Mark Beer</i>	Date Considered	11/23/05
-----------------------	------------------	--------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1: Unique citation designation number. 2: Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Substitute for Form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	10/719,102
Filing Date	November 21, 2003
First Named Inventor	Rao Kalla
Art Unit	1624
Examiner Name	
Attorney Docket Number	01-163-CIP2

Sheet 1 of 1

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No.	Document No.	Issue Date or Publication Date	Name of Patentee or Applicant of Cited Document	Class	Subclass	Filing Date if Appropriate
	1	4,452,788	June 5, 1984	Bristol et al			
	2	4,879,296	November 7, 1989	Daluge et al			
	3	4,558,051	December 10, 1985	Sunshine et al			
	4	4,593,095	June 3, 1986	Snyder et al			
	5	4,879,296	November 7, 1989	Daluge et al			
	6	5,532,368	July 2, 1996	Kufner-Muhl et al			
	7	5,641,784	June 24, 1997	Kufner-Muhl et al			
	8	5,714,494	February 3, 1998	Connell et al			
	9	6,060,481	May 9, 2000	La Noue et al			
	10	6,117,878	September 12, 2000	Linden			
	11	6,437,124	August 20, 2002	Daluge et al			
	12	6,545,002	April 8, 2003	Linden et al			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No.	Foreign Patent Document No.	Publication Date	Country	Class	Subclass	T
	13	EP 0386683	September 12, 1990	EP			
	14	EP 0986855-95855	November 17, 1999	EP			
	15	EP 1084710	March 21, 2001	EP			
	16	WO 9942093	August 26, 1999	WIPO			
	17	WO 0009507	February 24, 2000	WIPO			
	18	WO 9511681	May 4, 1995	WIPO			
	19	WO 0073307	December 7, 2000	WIPO			

**OTHER DOCUMENTS — NONPATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), Title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	20	JACOBSON K A et al: "1,3-Dialkylxanthine derivatives having high potency as antagonists at human A2B adenosine receptors", Drug Development Research, New York, NY, US, vol. 47, no. 1, 1999, pages 45-53, XP000942540, abstract; example 10D	
	21	KUZ' MENKO II et al, "Reactions of Theophyllines, Chemical Conversions of 8-Aminothetheophyllinates" Chemistry of Heterocyclic Compounds (A translation of Khimiya Geterotsiklicheskikh Soedinenii), Plenum Press Co., New York NY, US, vol. 36, no. 8, 2000 pages 963-970 XP001146936 ISSN: 0009-3122 examples 3K,3L,8	

Examiner Signature		Date Considered	11/23/05
--------------------	--	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.